Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4

Roberto Furlan, Alessandra Bergami, Rosmarie Lang, Elena Brambilla, Diego Franciotta, Vittorlo Martinelli, Giancarlo Comi, Paola Panina, Gianvito Martino

Research output: Contribution to journalArticle

Abstract

Systemic administration of interferon (IFN)-β has been recently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The immunological mechanism by which IFN-β ameliorates MS is still partially unknown. We measured the number of blood circulating CD4+, CD4-, CD8+, and CD8- T cells secreting IFN-γ and IL-4 in 26 RRMS patients followed for up to 9 months of an alternate day s.c. treatment with 8x16 IU of IFN-β1b. Compared to pre-treatment values, a significant (P+, CD4-, CD8+ and CD8- cells producing IFN-γ and of CD4+ and CD4- cells producing IL-4 was observed in MS patients. The IFN-β-associated effect was evident soon after the beginning of the treatment and persisted for the entire follow-up period. We did not observe any effect of IFN-β treatment on the percentage of IL-4-producing CD8+ and CD8- cells nor in that of natural killer (NK) cells producing IFN-γ. Our results show that IFN-β treatment in MS patients induces a profound and persistent down-regulation of the number of circulating T cells secreting IFN-γ and IL-4 thus suggesting a broader rather than a specific immunomodulatory effect of IFN-β in MS. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalJournal of Neuroimmunology
Volume111
Issue number1-2
DOIs
Publication statusPublished - Nov 1 2000

Fingerprint

Interleukin-4
Interferons
Multiple Sclerosis
T-Lymphocytes
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Natural Killer Cells
Down-Regulation

Keywords

  • Interferon-β
  • Intracellular cytokine staining
  • Multiple sclerosis
  • T helper cells

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

@article{aa58c4008fd44292b8d364b978e13ade,
title = "Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4",
abstract = "Systemic administration of interferon (IFN)-β has been recently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The immunological mechanism by which IFN-β ameliorates MS is still partially unknown. We measured the number of blood circulating CD4+, CD4-, CD8+, and CD8- T cells secreting IFN-γ and IL-4 in 26 RRMS patients followed for up to 9 months of an alternate day s.c. treatment with 8x16 IU of IFN-β1b. Compared to pre-treatment values, a significant (P+, CD4-, CD8+ and CD8- cells producing IFN-γ and of CD4+ and CD4- cells producing IL-4 was observed in MS patients. The IFN-β-associated effect was evident soon after the beginning of the treatment and persisted for the entire follow-up period. We did not observe any effect of IFN-β treatment on the percentage of IL-4-producing CD8+ and CD8- cells nor in that of natural killer (NK) cells producing IFN-γ. Our results show that IFN-β treatment in MS patients induces a profound and persistent down-regulation of the number of circulating T cells secreting IFN-γ and IL-4 thus suggesting a broader rather than a specific immunomodulatory effect of IFN-β in MS. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Interferon-β, Intracellular cytokine staining, Multiple sclerosis, T helper cells",
author = "Roberto Furlan and Alessandra Bergami and Rosmarie Lang and Elena Brambilla and Diego Franciotta and Vittorlo Martinelli and Giancarlo Comi and Paola Panina and Gianvito Martino",
year = "2000",
month = "11",
day = "1",
doi = "10.1016/S0165-5728(00)00377-5",
language = "English",
volume = "111",
pages = "86--92",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4

AU - Furlan, Roberto

AU - Bergami, Alessandra

AU - Lang, Rosmarie

AU - Brambilla, Elena

AU - Franciotta, Diego

AU - Martinelli, Vittorlo

AU - Comi, Giancarlo

AU - Panina, Paola

AU - Martino, Gianvito

PY - 2000/11/1

Y1 - 2000/11/1

N2 - Systemic administration of interferon (IFN)-β has been recently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The immunological mechanism by which IFN-β ameliorates MS is still partially unknown. We measured the number of blood circulating CD4+, CD4-, CD8+, and CD8- T cells secreting IFN-γ and IL-4 in 26 RRMS patients followed for up to 9 months of an alternate day s.c. treatment with 8x16 IU of IFN-β1b. Compared to pre-treatment values, a significant (P+, CD4-, CD8+ and CD8- cells producing IFN-γ and of CD4+ and CD4- cells producing IL-4 was observed in MS patients. The IFN-β-associated effect was evident soon after the beginning of the treatment and persisted for the entire follow-up period. We did not observe any effect of IFN-β treatment on the percentage of IL-4-producing CD8+ and CD8- cells nor in that of natural killer (NK) cells producing IFN-γ. Our results show that IFN-β treatment in MS patients induces a profound and persistent down-regulation of the number of circulating T cells secreting IFN-γ and IL-4 thus suggesting a broader rather than a specific immunomodulatory effect of IFN-β in MS. Copyright (C) 2000 Elsevier Science B.V.

AB - Systemic administration of interferon (IFN)-β has been recently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The immunological mechanism by which IFN-β ameliorates MS is still partially unknown. We measured the number of blood circulating CD4+, CD4-, CD8+, and CD8- T cells secreting IFN-γ and IL-4 in 26 RRMS patients followed for up to 9 months of an alternate day s.c. treatment with 8x16 IU of IFN-β1b. Compared to pre-treatment values, a significant (P+, CD4-, CD8+ and CD8- cells producing IFN-γ and of CD4+ and CD4- cells producing IL-4 was observed in MS patients. The IFN-β-associated effect was evident soon after the beginning of the treatment and persisted for the entire follow-up period. We did not observe any effect of IFN-β treatment on the percentage of IL-4-producing CD8+ and CD8- cells nor in that of natural killer (NK) cells producing IFN-γ. Our results show that IFN-β treatment in MS patients induces a profound and persistent down-regulation of the number of circulating T cells secreting IFN-γ and IL-4 thus suggesting a broader rather than a specific immunomodulatory effect of IFN-β in MS. Copyright (C) 2000 Elsevier Science B.V.

KW - Interferon-β

KW - Intracellular cytokine staining

KW - Multiple sclerosis

KW - T helper cells

UR - http://www.scopus.com/inward/record.url?scp=0034333099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034333099&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(00)00377-5

DO - 10.1016/S0165-5728(00)00377-5

M3 - Article

C2 - 11063825

AN - SCOPUS:0034333099

VL - 111

SP - 86

EP - 92

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -